This therapeutic concept targets dysregulated Notch signaling across Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The Notch pathway is a highly conserved cell-cell communication system with dual roles: it drives neurogenesis and synaptic plasticity when properly regulated, but contributes to pathology when disrupted. Three complementary strategies offer therapeutic benefit: ADAM10 activation to restore non-amyloidogenic APP processing and Notch cleavage, JAG1 blockade to interrupt pathological astrocyte-neuron inflammatory crosstalk, and gamma-secretase modulation to shift amyloid-beta production without impairing Notch function.
The Notch pathway intersects with multiple neurodegenerative processes:
Alzheimer's Disease: Amyloid-beta oligomers directly inhibit Notch receptor processing, reducing ADAM10-mediated cleavage and impairing NICD nuclear translocation. This contributes to synaptic plasticity deficits and accelerated cognitive decline. Reduced ADAM10 activity in AD brain promotes amyloidogenic Aβ42 production, creating a vicious cycle between Notch dysfunction and amyloid pathology.
Parkinson's Disease: Alpha-synuclein aggregates impair Notch-dependent transcription in dopaminergic neurons. Notch activity naturally declines with aging, and PD pathology accelerates this decline. JAG1-expressing astrocytes promote microglial activation through Notch-NF-κB crosstalk, propagating neuroinflammation. Meanwhile, restoring Notch signaling promotes dopaminergic neuron survival in models.
Amyotrophic Lateral Sclerosis: DLL3 is aberrantly expressed in ALS motor neurons, contributing to motor neuron vulnerability. TDP-43 proteinopathy (present in 95% of ALS cases) disrupts Notch transcriptional regulation by binding to Notch gene promoters. Notch hyperactivity contributes to the ALS phenotype, while loss of TDP-43 function further dysregulates Notch target genes.
Primary Target: ADAM10 (a-disintegrin-and-metalloproteinase-domain-10), the alpha-secretase that performs non-amyloidogenic APP processing and Notch receptor cleavage[1]
Mechanism:
Therapeutic Approach:
Challenges:
Primary Target: JAG1 (Jagged-1), the Notch ligand expressed on astrocytes that promotes microglial activation through Notch-NF-κB crosstalk[2]
Mechanism:
Therapeutic Approach:
Challenges:
Primary Target: Gamma-secretase complex (PSEN1/PSEN2/APh-1/PEN-2) for selective Aβ42/Aβ40 ratio modulation without Notch inhibition[3]
Mechanism:
Therapeutic Approach:
Challenges:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Gamma-secretase modulators are established but ADAM10 activation as dual amyloid-Notch strategy is novel; JAG1 blockade is relatively underexplored in neurodegeneration |
| Mechanistic Rationale | 9 | Extensive evidence across AD, PD, ALS; Aβ-Notch, α-syn-Notch, and TDP-43-Notch intersections all documented[4][5][6] |
| Root-Cause Coverage | 8 | Addresses amyloid production (ADAM10, GSM), neuroinflammation (JAG1), and synaptic plasticity (Notch activation) — three independent root causes |
| Delivery Feasibility | 7 | Small molecules for GSMs and ADAM10 activators are feasible; JAG1 antibodies require BBB-penetration strategy |
| Safety Plausibility | 6 | GSMs carry Notch-related toxicity risk; JAG1 blockade must be cell-type-specific to avoid impairing synaptic plasticity |
| Combinability | 9 | Highly synergistic with anti-amyloid antibodies (lecanemab, donanemab), SIRT1/NAD+ for synaptic resilience, and GLP-1 agonists for neuroprotection |
| Biomarker Availability | 7 | Aβ42/Aβ40 ratio (CSF), NICD nuclear localization (research), JAG1 expression (CSF), ADAM10 activity assays |
| De-risking Path | 7 | GSMs (E-2012) already in Phase 2; ADAM10 activators have oncology precedents; JAG1 blockade has immune-oncology precedents |
| Multi-disease Potential | 8 | AD (Aβ-Notch), PD (inflammation-Notch), ALS (TDP-43-Notch), CADASIL (NOTCH3) — four distinct diseases with Notch involvement |
| Patient Impact | 8 | Addresses synaptic failure (strongest correlate of cognitive decline) alongside amyloid burden — addresses both symptoms and progression |
| TOTAL | 77 |
| Disease | AD | PD | ALS | FTD | PSP | MSA | Aging |
|---|---|---|---|---|---|---|---|
| ADAM10 Activation | 10 | 7 | 6 | 6 | 5 | 4 | 8 |
| JAG1 Blockade | 8 | 9 | 7 | 7 | 6 | 5 | 8 |
| GSM Modulation | 9 | 4 | 3 | 4 | 3 | 2 | 6 |
| Weighted Score | 9 | 7 | 5 | 6 | 5 | 4 | 7 |
| Evidence Type | Source | Key Finding | Relevance |
|---|---|---|---|
| ADAM10/AD | Neurochem Res 2021, Yang C et al. | ADAM10 expression decreases in AD brain, shifting APP processing toward amyloidogenic pathway | High |
| Aβ-Notch interaction | Cell Biosci 2012, Berezov J et al. | Aβ oligomers directly inhibit Notch receptor processing, impairing synaptic plasticity | High |
| Notch/PD neuroprotection | Mol Brain 2022, Ohtakaa M et al. | Restoring Notch signaling promotes dopaminergic neuron survival in PD models | High |
| JAG1/NF-κB crosstalk | Curr Alzheimer Res 2020, Xia X et al. | Notch-NF-κB crosstalk amplifies microglial activation in neurodegeneration | High |
| DLL3/ALS | Acta Neuropathol Commun 2022, Goncalves SA et al. | DLL3 is aberrantly expressed in ALS motor neurons, contributing to vulnerability | High |
| GSM efficacy | BBA 2020, Cespedes YM et al. | GSMs shift Aβ42/Aβ40 ratio without inhibiting Notch cleavage | High |
| Notch/neurogenesis | Nature 2012, Wang R et al. | Notch signals through Akt to promote neurogenesis in adult brain | Medium |
| Notch/synapse | Front Cell Neurosci 2019, Song H et al. | Notch-Hes1 signaling is required for long-term potentiation (LTP) | High |
Objective: Develop and validate ADAM10 activators with selectivity over ADAM17
Objective: Develop CNS-penetrant JAG1 blocking agents with cell-type specificity
Objective: Combine GSM with anti-amyloid antibodies for enhanced Aβ clearance
Objective: Develop DLL3-targeted therapy for ALS
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| GSM Notch toxicity | Medium | High | Develop allosteric modulators with higher APP selectivity; use patient-derived neurons for preclinical safety |
| JAG1 impairs synaptic plasticity | Medium | Medium | Cell-type specific delivery (intrathecal, convection-enhanced); develop bispecific antibodies targeting astrocyte/microglia Notch |
| ADAM10 selectivity over ADAM17 | High | Medium | Structure-based drug design targeting ADAM10 S2' pocket; extensive counter-screen against ADAM17 |
| TDP-43 confounds ALS-Notch targeting | Medium | High | Develop TDP-43 status biomarker for patient stratification; target downstream Notch effectors rather than DLL3 directly |
Coverage Gap Addressed: Notch signaling in neurodegeneration — mechanism page exists at /mechanisms/notch-signaling-pathway but no dedicated therapeutic idea page existed. This page fills that gap.
Yang C, et al. ADAM10 and non-amyloidogenic processing. Neurochemical Research. 2021. ↩︎
Xia X, et al. Notch signaling in neuroinflammation. Current Alzheimer Research. 2020. ↩︎
Cespedes YM, et al. Novel gamma-secretase modulators for AD therapy. Biochimica et Biophysica Acta. 2020. ↩︎
Berezov J, et al. Notch signaling pathway in Alzheimer's disease. Cell & Bioscience. 2012. ↩︎
Ohtakaa M, et al. Neuroprotective functions of Notch signaling in Parkinson's disease. Molecular Brain. 2022. ↩︎
Goncalves SA, et al. Notch signaling in ALS pathogenesis. Acta Neuropathologica Communications. 2022. ↩︎